Final version mark-up expected in coming weeks
The Senate Health, Education, Labor and Pensions (HELP) Committee released a discussion draft Tuesday of the FDA Safety and Landmark Achievements (FDASLA) Act – legislation reauthorizing user fee agreements for prescription drug, generic drug, biosimilar and medical devices. The Energy and Commerce Committee unanimously passed the House version Wednesday.
These bipartisan announcements mark critical step in the legislative process to ensure our member companies can continue driving innovation and create the next generation of life-saving products.
This has been a top priority for Medical Alley Association’s new Government Affairs and Policy team, comprised of Shannon Watson, Senior Director of Government Affairs and Policy & Ben Wagner, Public Policy Communications Specialist. Leveraging input from member companies – MAA submitted technical comments related to the legislation, both to individual lawmakers and the HELP Committee – specifically on Medical Device Certification and Change Control Protocols.
Senate committee members are expected to mark-up a final version of the FDASLA Act in the coming weeks.
For learn more about FDASLA draft legislation announcement, click here.
To read the full text of FDASLA Act, click here.
